| Amy L Thompson, MS, OTR/L | |
|
300 6th St, Rapid City, SD 57701-5034 | |
| (605) 394-1813 | |
| Not Available |
| Full Name | Amy L Thompson |
|---|---|
| Gender | Female |
| Speciality | Occupational Therapist |
| Location | 300 6th St, Rapid City, South Dakota |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1073663407 | NPI | - | NPPES |
| 542182168 | Other | AK | TAX ID |
| OT33692 | Medicaid | AK |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 225X00000X | Occupational Therapist | 1381 (Alaska) | Secondary |
| 225X00000X | Occupational Therapist | 0731 (South Dakota) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Amy L Thompson, MS, OTR/L 300 6th St, Rapid City, SD 57701-5034 Ph: (605) 394-1813 | Amy L Thompson, MS, OTR/L 300 6th St, Rapid City, SD 57701-5034 Ph: (605) 394-1813 |
News Archive
Researchers at the University of York are beginning a major study into the ethical and personal issues raised by a potential revolution in healthcare, which could incorporate individualised medical care – pharmacogenetics - into clinical practice.
Red wine may protect against the development of lung cancer in men, suggests research in Thorax, with each daily glass conferring additional benefit. No other type of alcohol seemed to have the same effect, the study found.
The study looked at the ability of an extract of pomegranate fruit against Interleukin-1b (IL-1b), a pro-inflammatory protein molecule that plays a key role in cartilage degradation in osteoarthritis.
Onyx Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval of Kyprolis (carfilzomib) for Injection, a proteasome inhibitor, indicated for the treatment of patients with multiple myeloma who have received at least two prior therapies, including bortezomib and an immunomodulatory agent, and have demonstrated disease progression on or within 60 days of completion of the last therapy.
A new clinical research study at Roswell Park Cancer Institute (RPCI) will assess the safety and efficacy of a novel immunotherapy approach to treating advanced melanoma. Developed at RPCI by Roswell Park researchers, the investigational vaccine shows promise for treating tumors in patients with stage III/stage IV melanoma, and perhaps as a future therapy for other solid-tumor cancers as well.
› Verified 2 days ago
Rebecca Lavon Hedeen, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 1001 Allen Ave, Rapid City, SD 57701 Phone: 605-342-0255 | |
Alan Schulte, OT Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 353 Fairmont Blvd, Rapid City, SD 57701 Phone: 605-719-1100 Fax: 605-719-7680 | |
Ms. Mary Caviston, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 916 Mountain View Rd, Rapid City, SD 57702 Phone: 605-343-8577 | |
Katie Ness, Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 2500 Arrowhead Dr, Rapid City, SD 57702 Phone: 605-348-0285 | |
Krista Elizabeth Crook, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 7110 Jordan Dr, Rapid City, SD 57702 Phone: 605-791-7400 Fax: 605-791-7401 | |
Jessica Flett, Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 353 Fairmont Blvd, Rapid City, SD 57701 Phone: 605-755-1140 | |
Jennifer Marie Styles, Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 353 Fairmont Blvd, Rapid City, SD 57701 Phone: 605-755-1140 |